Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Bicara Therapeutics Inc (BCAX)

Bicara Therapeutics Inc (BCAX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Fri Apr 3, 7:30AM CDT

BOSTON, April 03, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients...

BCAX : 22.14 (+4.83%)
Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update GlobeNewswire - Mon Mar 30, 6:30AM CDT

Selected 1500mg weekly of ficerafusp alfa as the optimal dose and initiated Phase 3 of the FORTIFI-HN01 pivotal trial; interim analysis expected mid-2027 Announced development of a less frequent loading...

BCAX : 22.14 (+4.83%)
Bicara Has a Cancer Drug Wall Street Is Starting to Believe In. Earnings Will Tell Us If That Faith Is Earned. Barchart - Sun Mar 29, 4:00PM CDT

Barchart Research What to Expect from BCAX Earnings BCAX Generated March 27, 2026 Current Price $18.37 EPS Estimate $-0.72 Consensus Rating Strong Buy Average Move 5.47% Bicara Has a Cancer Drug Wall Street...

BCAX : 22.14 (+4.83%)
Bicara Has a Cancer Drug Wall Street Is Starting to Believe In. Earnings Will Tell Us If That Faith Is Earned. Barchart - Sat Mar 28, 4:01PM CDT

Barchart Research What to Expect from BCAX Earnings BCAX Generated March 27, 2026 Current Price $18.37 EPS Estimate $-0.72 Consensus Rating Strong Buy Average Move 5.47% Bicara Has a Cancer Drug Wall Street...

BCAX : 22.14 (+4.83%)
Bicara Has a Cancer Drug Wall Street Is Starting to Believe In. Earnings Will Tell Us If That Faith Is Earned. Barchart - Fri Mar 27, 4:02PM CDT

Barchart Research What to Expect from BCAX Earnings BCAX Generated March 27, 2026 Current Price $18.37 EPS Estimate $-0.72 Consensus Rating Strong Buy Average Move 5.47% Bicara Has a Cancer Drug Wall Street...

BCAX : 22.14 (+4.83%)
Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET GlobeNewswire - Mon Mar 23, 7:30AM CDT

BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients...

BCAX : 22.14 (+4.83%)
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Wed Mar 4, 7:30AM CST

BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients...

BCAX : 22.14 (+4.83%)
Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares GlobeNewswire - Thu Feb 26, 3:01PM CST

BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with...

BCAX : 22.14 (+4.83%)
Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants GlobeNewswire - Tue Feb 24, 10:13PM CST

BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with...

BCAX : 22.14 (+4.83%)
Bicara Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire - Tue Feb 24, 3:01PM CST

BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with...

BCAX : 22.14 (+4.83%)

Barchart Exclusives

Ignore the Anthropic Panic and Keep Buying Palantir Stock, Says Wedbush Barchart - Mon Apr 13, 3:53PM CDT
Wedbush urges investors to tune out the Anthropic noise and keep buying Palantir, betting on its strong AI moat and solid fundamentals. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.